CA3006365A1 - Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires - Google Patents

Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires Download PDF

Info

Publication number
CA3006365A1
CA3006365A1 CA3006365A CA3006365A CA3006365A1 CA 3006365 A1 CA3006365 A1 CA 3006365A1 CA 3006365 A CA3006365 A CA 3006365A CA 3006365 A CA3006365 A CA 3006365A CA 3006365 A1 CA3006365 A1 CA 3006365A1
Authority
CA
Canada
Prior art keywords
compound
group
ethyl
propionylamino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3006365A
Other languages
English (en)
French (fr)
Inventor
Herve Poras
Michel WURM
Stephane Melik Parsadaniantz
Annabelle REAUX-LE GOAZIGO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaleads SA
Original Assignee
Pharmaleads SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaleads SA filed Critical Pharmaleads SA
Publication of CA3006365A1 publication Critical patent/CA3006365A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
CA3006365A 2015-11-30 2016-11-30 Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires Pending CA3006365A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1561598 2015-11-30
FR1561598A FR3044227B1 (fr) 2015-11-30 2015-11-30 Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
PCT/EP2016/079285 WO2017093322A1 (fr) 2015-11-30 2016-11-30 Dérivés aminophosphiniques pour la prévention et le traitement des douleurs oculaires

Publications (1)

Publication Number Publication Date
CA3006365A1 true CA3006365A1 (fr) 2017-06-08

Family

ID=55346018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3006365A Pending CA3006365A1 (fr) 2015-11-30 2016-11-30 Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires

Country Status (15)

Country Link
US (2) US20180344753A1 (enExample)
EP (1) EP3383403B1 (enExample)
JP (1) JP6889176B2 (enExample)
KR (1) KR102657652B1 (enExample)
CN (2) CN112121008A (enExample)
BR (1) BR112018010007A2 (enExample)
CA (1) CA3006365A1 (enExample)
DK (1) DK3383403T3 (enExample)
ES (1) ES2773148T3 (enExample)
FR (1) FR3044227B1 (enExample)
IL (1) IL259562B (enExample)
MX (1) MX382921B (enExample)
TW (1) TWI729039B (enExample)
WO (1) WO2017093322A1 (enExample)
ZA (1) ZA201804037B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3592361B1 (fr) * 2017-03-09 2023-09-13 IACTA Pharmaceuticals, Inc. Dérivés aminophosphiniques pour la prévention et le traitement de l'inflammation oculaire
FR3063635B1 (fr) * 2017-03-09 2019-06-07 Pharmaleads Derives aminophosphiniques pour la prevention et le traitement de l'inflammation oculaire
FR3104581B1 (fr) * 2019-12-11 2021-11-26 Pharmaleads Procédé de préparation industrielle du sel disodique de ((2S)-3-([1,1'-biphenyl]-4-yl)-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-L-alanine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
FR2755135B1 (fr) * 1996-10-25 2002-12-27 Inst Nat Sante Rech Med Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent
CA2275167C (en) * 1996-12-16 2008-10-28 Alcon Laboratories, Inc. The topical use of kappa opioid agonists to treat ocular pain
FR2777780B1 (fr) * 1998-04-22 2001-05-04 Inst Nat Sante Rech Med Derives d'(alpha-aminophosphino) peptides, leur procede de preparation et les compositions qui les contiennent
FR2934267B1 (fr) * 2008-07-23 2010-08-13 Pharmaleads Derives aminophosphiniques utiles dans le traitement de la douleur
FR2934627B1 (fr) 2008-07-29 2010-08-13 Paul Marie Bernard Dispositif de positionnement et de calage d'un garde corps escamotable sur plateforme support de banches
KR20150119082A (ko) * 2013-02-13 2015-10-23 노파르티스 아게 국소 안구 진통제

Also Published As

Publication number Publication date
WO2017093322A1 (fr) 2017-06-08
FR3044227B1 (fr) 2017-11-24
IL259562A (en) 2018-07-31
EP3383403B1 (fr) 2019-12-25
JP6889176B2 (ja) 2021-06-18
TWI729039B (zh) 2021-06-01
MX2018006580A (es) 2018-08-01
ES2773148T3 (es) 2020-07-09
CN108289901A (zh) 2018-07-17
KR20180095555A (ko) 2018-08-27
IL259562B (en) 2020-08-31
US20190167701A1 (en) 2019-06-06
BR112018010007A2 (pt) 2018-11-21
ZA201804037B (en) 2020-07-29
FR3044227A1 (fr) 2017-06-02
CN112121008A (zh) 2020-12-25
KR102657652B1 (ko) 2024-04-15
MX382921B (es) 2025-03-13
DK3383403T3 (da) 2020-03-16
JP2018536714A (ja) 2018-12-13
HK1259181A1 (zh) 2019-11-29
US20180344753A1 (en) 2018-12-06
TW201726146A (zh) 2017-08-01
EP3383403A1 (fr) 2018-10-10
US10688113B2 (en) 2020-06-23
CN108289901B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
US5891913A (en) Ophthalmic and aural compositions containing diclofenac potassium
AU2003202219B2 (en) Methods for treating hearing loss
US20070254841A1 (en) Formulations and methods for treating dry eye
JPH03503159A (ja) 眼科用サイクロスポリン組成物
EP3383403B1 (fr) Dérivés aminophosphiniques pour la prévention et le traitement des douleurs oculaires
JPS6225645B2 (enExample)
EP0403360B1 (fr) Utilisation de phényléthanolamines pour la préparation de médicaments pour les affections oculaires
IT9020968A1 (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
EP0630240B1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists
HU227940B1 (hu) Flunarizin alkalmazása zöldhályog helyi kezelésére alkalmas gyógyszerkészítmény elõállítására
JP2023067982A (ja) 眼の炎症を予防及び治療するためのアミノホスフィン誘導体
FR3063635B1 (fr) Derives aminophosphiniques pour la prevention et le traitement de l'inflammation oculaire
HK40042434A (en) Aminophosphinic derivatives for preventing and treating eye pain
HK1259181B (en) Aminophosphinic derivatives for preventing and treating eye pain
FR2773076A1 (fr) Utilisation de la flavine-adenine-dinucleotide pour la preparation de compositions ophtalmiques utiles pour le traitement de l'oeil sec
WO2021015647A1 (ru) Глазные капли для лечения возрастной катаракты ядерного вида

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211101

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241028

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241028

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241029

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250707

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250707

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260529

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713